Last reviewed 2026-04-19 · How we verify

EG110A

EG 427 · Phase 1 active Small molecule

At a glance

Generic name	EG110A
Sponsor	EG 427
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EG110A CI brief — competitive landscape report
EG110A updates RSS · CI watch RSS
EG 427 portfolio CI